Vertex Pharmaceuticals Inc
VRTX· Nasdaq
Released Feb 12, 2026, after the close
10-K filed Feb 13, 2026, 44 days after period end · 0000875320-26-000056
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $3.19B | $2.91B | $2.52B | $2.30B |
| Net Income | $1.19B |
Vertex Pharmaceuticals Inc · CIK 875320 · Engraved from SEC EDGAR
| $913.00M |
| $968.80M |
| $818.90M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.